Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S lowered its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 12.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 15,893 shares of the company's stock after selling 2,269 shares during the period. BI Asset Management Fondsmaeglerselskab A S owned 0.05% of Medpace worth $5,280,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Pallas Capital Advisors LLC increased its holdings in Medpace by 179.7% during the 4th quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company's stock valued at $1,086,000 after purchasing an additional 2,101 shares in the last quarter. Barclays PLC raised its position in shares of Medpace by 71.9% during the third quarter. Barclays PLC now owns 19,781 shares of the company's stock worth $6,603,000 after purchasing an additional 8,275 shares during the period. Sanctuary Advisors LLC raised its holdings in shares of Medpace by 20.5% during the fourth quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company's stock worth $1,738,000 after acquiring an additional 844 shares during the period. SYM FINANCIAL Corp bought a new stake in shares of Medpace in the fourth quarter valued at about $320,000. Finally, Tokio Marine Asset Management Co. Ltd. bought a new stake in shares of Medpace in the fourth quarter worth $9,335,000. Institutional investors and hedge funds own 77.98% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently commented on MEDP. Mizuho decreased their price target on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 9th. Leerink Partners began coverage on shares of Medpace in a report on Monday, March 24th. They issued a "market perform" rating and a $330.00 target price for the company. Robert W. Baird reduced their price objective on Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a research report on Wednesday. William Blair reiterated a "market perform" rating on shares of Medpace in a report on Tuesday. Finally, Truist Financial reduced their target price on Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a report on Wednesday. Eleven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $349.30.

Medpace Trading Up 3.2 %

Shares of MEDP traded up $8.94 during mid-day trading on Wednesday, hitting $291.22. The company's stock had a trading volume of 1,419,454 shares, compared to its average volume of 338,215. The firm has a market capitalization of $8.80 billion, a price-to-earnings ratio of 23.06, a PEG ratio of 3.81 and a beta of 1.46. The company's 50-day moving average is $315.38 and its 200-day moving average is $332.24. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. The firm had revenue of $558.57 million for the quarter, compared to analyst estimates of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same quarter in the prior year, the business earned $3.20 earnings per share. As a group, sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.